Literature DB >> 1701920

Effect of a free sulphydryl group on expression of HLA-B27 specificity.

J R Archer1, M A Whelan, S S Badakere, I L McLean, I V Archer, V R Winrow.   

Abstract

Sequence studies indicate that the alpha-1 domain of the HLA-B27 molecule has a characteristic unpaired cysteine residue at position 67, adjacent, because of secondary structure, to a lysine at position 70. Simple chemical considerations predict that this cysteine should have an exceptionally reactive sulphydryl group. We have shown by ELISA and flow cytometry that the binding of some monoclonal antibodies to B27 on lymphoid cell lines can be inhibited by reagents which react with sulphydryl groups. However this inhibition is never complete: the evidence suggests 2 forms of B27 molecule, one of which is already blocked. We propose that some HLA molecules with oxidised sulphydryls are recognised as different from the reduced forms. Whether they are also recognised as foreign will depend on an individual's history of thymic learning. Oxidation to 'foreign' HLA in the adult is likely to predispose to inflammatory reactions.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1701920     DOI: 10.3109/03009749009097057

Source DB:  PubMed          Journal:  Scand J Rheumatol Suppl        ISSN: 0301-3847


  3 in total

Review 1.  HLA-B27 subtypes: implications for the spondyloarthropathies.

Authors:  L MacLean
Journal:  Ann Rheum Dis       Date:  1992-08       Impact factor: 19.103

Review 2.  HLA-B27 associated spondyloarthropathy, an autoimmune disease based on crossreactivity between bacteria and HLA-B27?

Authors:  J H Ringrose
Journal:  Ann Rheum Dis       Date:  1999-10       Impact factor: 19.103

3.  Crosslinks Between Human Leukocyte Antigen DRB1*01 and Human Leukocyte Antigen DRB1*13 Allelic Variants and Occurrence of Rheumatoid Arthritis in Patients From Federation of Bosnia and Herzegovina.

Authors:  Elma Fejzic; Amela Sahovic; Sanela Sisic; Andi Alijagic; Damir Suljevic
Journal:  Arch Rheumatol       Date:  2017-05-25       Impact factor: 1.472

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.